What it's for (Indications)
- Lynestrenol, a synthetic progestogen, is primarily indicated for various gynecological conditions requiring progestogenic action.
- This includes its use as an oral contraceptive, often in combination formulations, or as a progestogen-only pill, particularly when estrogens are contraindicated.
- It is effectively utilized in the management of menstrual disorders such as menorrhagia (heavy menstrual bleeding), metrorrhagia (irregular or prolonged uterine bleeding), oligomenorrhea (infrequent menstruation), and secondary amenorrhea (absence of menstruation for several cycles).
- Furthermore, lynestrenol is prescribed for the treatment of endometriosis, a condition characterized by the growth of endometrial-like tissue outside the uterus, by inducing decidualization and atrophy of ectopic endometrial implants.
- It also finds application in conjunction with estrogen therapy for hormone replacement therapy (HRT) to counteract estrogen-induced endometrial hyperplasia and reduce the risk of endometrial cancer in women with an intact uterus, and can be used in cases of benign breast disease or palliative treatment of endometrial carcinoma.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of lynestrenol (Omatril) is highly individualized and depends significantly on the specific indication, patient response, and concurrent therapies. For oral contraception (progestogen-only pill, POP), a common regimen involves a continuous daily dose of 0.5 mg, taken at the same time each day without interruption. In the management of menstrual disorders such as menorrhagia or metrorrhagia, doses typically range from 5 mg to 10 mg daily for 5 to 10 days, usually starting from a specific day of the menstrual cycle, followed by a withdrawal bleed. For the treatment of endometriosis, a more prolonged and sometimes escalating regimen may be employed, starting with 5 mg daily and potentially increasing to 10 mg or more daily for 6 to 9 months, aiming to induce amenorrhea and atrophy of endometrial lesions. As a component of hormone replacement therapy (HRT) to protect the endometrium in women with an intact uterus, doses generally range from 1 mg to 2.5 mg daily, either continuously or cyclically for a specific number of days each month, in combination with estrogen. Dosage for palliative treatment of endometrial carcinoma can be significantly higher, up to 30 mg daily. |
Safety & Warnings
Common Side Effects
- Conditions that may worsen fluid retention, such as epilepsy, hypertension, migraine, asthma, or cardiac dysfunction, should be closely monitored.
- Lynestrenol can also decrease glucose tolerance, necessitating close monitoring in diabetic patients.
Serious Warnings
- Black Box Warning: None
- Patients should consult their doctor before using lynestrenol during pregnancy or while lactating.
- Due to a reported risk of drowsiness, driving should be avoided while on this medication.
- Patients with liver disease or kidney disease should consult their doctor for a thorough evaluation before use.
- The use of alcohol should be limited or avoided.
- Caution is advised when using lynestrenol or any progestogen in conditions that may worsen fluid retention (e.
- g.
- , epilepsy, hypertension, migraine, asthma, or cardiac dysfunction) and in diabetic patients due to the potential for decreased glucose tolerance.
How it Works (Mechanism of Action)
Lynestrenol is a synthetic progestogen that exhibits potent progestational activity following oral administration. It functions as a prodrug, being rapidly and extensively metabolized in the liver to its pharmacologically active metabolite, norethisterone (norethindrone). Norethisterone exerts its effects by binding to progesterone receptors in various target tissues, including the uterus, pituitary gland, and hypothalamus. In the context of contraception, lynestrenol primarily acts by thickening cervical mucus, thereby creating a barrier hostile to sperm penetration. It also suppresses the hypothalamic-pituitary-ovarian axis, leading to inhibition of ovulation by preventing the luteinizing hormone (LH) surge and disrupting follicular development. Furthermore, it induces changes in the endometrium, making it atrophic and unsuitable for implantation of a fertilized ovum. For conditions like endometriosis and menstrual disorders, lynestrenol's progestogenic effects lead to decidualization and subsequent atrophy of the endometrial lining, both uterine and ectopic, and stabilization of the endometrium, preventing dysfunctional bleeding. In hormone replacement therapy, it serves to oppose the proliferative effects of estrogen on the endometrium, thereby reducing the risk of endometrial hyperplasia and carcinoma.
Commercial Brands (Alternatives)
No other brands found for this formula.